75 related articles for article (PubMed ID: 11268469)
1. Clinical pharmacokinetics and metabolism of paclitaxel after polychemotherapy with the cytoprotective agent amifostine.
Czejka M; Schueller J; Eder I; Reznicek G; Kraule C; Zeleni U; Freitag R
Anticancer Res; 2000; 20(5C):3871-7. PubMed ID: 11268469
[TBL] [Abstract][Full Text] [Related]
2. Influence of the cyto-protective agent amifostine on the pharmacokinetics of low-dose Paclitaxel.
Juan O; Rocher A; Sánchez A; Sánchez JJ; Alberola V
Chemotherapy; 2005 Jul; 51(4):200-5. PubMed ID: 15985759
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.
Movsas B; Scott C; Langer C; Werner-Wasik M; Nicolaou N; Komaki R; Machtay M; Smith C; Axelrod R; Sarna L; Wasserman T; Byhardt R
J Clin Oncol; 2005 Apr; 23(10):2145-54. PubMed ID: 15800308
[TBL] [Abstract][Full Text] [Related]
4. Clinical trial and pharmacokinetic study of combination paclitaxel and carboplatin in patients with epithelial ovarian cancer.
Yamamoto R; Kaneuchi M; Nishiya M; Todo Y; Takeda M; Okamoto K; Negishi H; Sakuragi N; Fujimoto S; Hirano T
Cancer Chemother Pharmacol; 2002 Aug; 50(2):137-42. PubMed ID: 12172979
[TBL] [Abstract][Full Text] [Related]
5. Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer.
Leong SS; Tan EH; Fong KW; Wilder-Smith E; Ong YK; Tai BC; Chew L; Lim SH; Wee J; Lee KM; Foo KF; Ang P; Ang PT
J Clin Oncol; 2003 May; 21(9):1767-74. PubMed ID: 12721253
[TBL] [Abstract][Full Text] [Related]
6. Amifostine before chemotherapy: improved tolerance profile of the subcutaneous over the intravenous route.
Koukourakis MI; Simopoulos C; Minopoulos G; Patlakas G; Polychronidis A; Limberis V; Romanides K; Pitiacoudis M; Manolas C
Clin Cancer Res; 2003 Aug; 9(9):3288-93. PubMed ID: 12960114
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.
Liu J; Kraut E; Bender J; Brooks R; Balcerzak S; Grever M; Stanley H; D'Ambrosio S; Gibson-D'Ambrosio R; Chan KK
Cancer Chemother Pharmacol; 2002 May; 49(5):367-74. PubMed ID: 11976830
[TBL] [Abstract][Full Text] [Related]
8. A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application.
Veltkamp SA; Alderden-Los C; Sharma A; Rosing H; Beijnen JH; Schellens JH
Cancer Chemother Pharmacol; 2007 Jan; 59(1):43-50. PubMed ID: 16680462
[TBL] [Abstract][Full Text] [Related]
9. Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group.
Moore DH; Donnelly J; McGuire WP; Almadrones L; Cella DF; Herzog TJ; Waggoner SE;
J Clin Oncol; 2003 Nov; 21(22):4207-13. PubMed ID: 14615449
[TBL] [Abstract][Full Text] [Related]
10. Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763.
Miller AA; Rosner GL; Egorin MJ; Hollis D; Lichtman SM; Ratain MJ
Clin Cancer Res; 2004 Dec; 10(24):8325-31. PubMed ID: 15623609
[TBL] [Abstract][Full Text] [Related]
11. Clindamycin-paclitaxel pharmacokinetic interaction in ovarian cancer patients.
Fruscio R; Lissoni AA; Frapolli R; Corso S; Mangioni C; D'Incalci M; Zucchetti M
Cancer Chemother Pharmacol; 2006 Sep; 58(3):319-25. PubMed ID: 16362296
[TBL] [Abstract][Full Text] [Related]
12. Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors.
Kobayashi H; Eckhardt SG; Lockridge JA; Rothenberg ML; Sandler AB; O'Bryant CL; Cooper W; Holden SN; Aitchison RD; Usman N; Wolin M; Basche ML
Cancer Chemother Pharmacol; 2005 Oct; 56(4):329-36. PubMed ID: 15906031
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel.
Muindi JR; Peng Y; Potter DM; Hershberger PA; Tauch JS; Capozzoli MJ; Egorin MJ; Johnson CS; Trump DL
Clin Pharmacol Ther; 2002 Dec; 72(6):648-59. PubMed ID: 12496746
[TBL] [Abstract][Full Text] [Related]
14. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol).
Sparreboom A; Scripture CD; Trieu V; Williams PJ; De T; Yang A; Beals B; Figg WD; Hawkins M; Desai N
Clin Cancer Res; 2005 Jun; 11(11):4136-43. PubMed ID: 15930349
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic study of paclitaxel administered with or without the cytoprotective agent amifostine, and given as a single agent or in combination with epirubicin and cisplatin in patients with advanced solid tumors.
Van den Brande J; Nannan Panday VR; Hoekman K; Rosing H; Huijskes RV; Verheijen RH; Beijnen JH; Vermorken JB
Am J Clin Oncol; 2001 Aug; 24(4):401-3. PubMed ID: 11474273
[TBL] [Abstract][Full Text] [Related]
16. Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat.
Liu J; Kraut EH; Balcerzak S; Grever M; D'Ambrosio S; Chan KK
Cancer Chemother Pharmacol; 2002 Dec; 50(6):445-53. PubMed ID: 12451470
[TBL] [Abstract][Full Text] [Related]
17. Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B.
Akerley W; Herndon JE; Egorin MJ; Lyss AP; Kindler HL; Savarese DM; Sherman CA; Rosen DM; Hollis D; Ratain MJ; Green MR
Cancer; 2003 May; 97(10):2480-6. PubMed ID: 12733147
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and tumor uptake of a derivatized form of paclitaxel associated to a cholesterol-rich nanoemulsion (LDE) in patients with gynecologic cancers.
Dias ML; Carvalho JP; Rodrigues DG; Graziani SR; Maranhão RC
Cancer Chemother Pharmacol; 2007 Jan; 59(1):105-11. PubMed ID: 16699792
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic drug monitoring of paclitaxel (Zisu) in cancer patients.
Wu D; Liang Y; Liu Q
J Environ Pathol Toxicol Oncol; 2000; 19(1-2):77-80. PubMed ID: 10905511
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer.
Gelmon K; Eisenhauer E; Bryce C; Tolcher A; Mayer L; Tomlinson E; Zee B; Blackstein M; Tomiak E; Yau J; Batist G; Fisher B; Iglesias J
J Clin Oncol; 1999 Oct; 17(10):3038-47. PubMed ID: 10506598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
